Estrogens, phytoestrogens, and breast cancer

Advances in Experimental Medicine and Biology

Volumn 401, Issue , 1996, Pages 63-85

  Clarke, Robert ^a,b   Hilakivi Clarke, Leena ^a,b   Cho, Elizabeth ^a   James, Mattie R ^a   Leonessa, Fabio ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; FLAVANONE; FLAVONE; ISOFLAVONE; PHYTOESTROGEN; ZEARALENONE;

BREAST CANCER; BREAST DEVELOPMENT; CANCER GROWTH; CARCINOGENESIS; CONFERENCE PAPER; FEMALE; HORMONE ACTION; HORMONE RESPONSE; HUMAN; LIGAND BINDING; MENSTRUAL CYCLE; PRIORITY JOURNAL;

EID: 0029792649     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4613-0399-2_6     Document Type: Conference Paper

References (141)

1. G.T. Beatson, On the treatment of inoperable cases of carcinoma of the mamma: suggestions from a new method of treatment, with illustrative cases, Lancet ii:104-107 (1896).
2. J.R. Daling, K.E. Malone, L.F. Voigt, E. White, and N.S. Weiss, Risk of breast cancer in young women: relationship to induced abortion, J Natl Cancer Inst 86:1584-1592 (1994).
3. B.E. Henderson, R. Ross, and L. Bernstein, Estrogens as a cause of human cancer, Cancer Res 48:246-253 (1988).
4. R. Clarke, N. Brünner, B.S. Katzenellenbogen, E.W. Thompson, M.J. Norman, C. Koppi, S. Paik, M.E. Lippman, and R.B. Dickson, Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells, Proc Natl Acad Sci USA 86:3649-3653 (1989).
5. K. Seibert, S.M. Shafie, T.J. Triche, J.J. Whang-Peng, S.J. O'Brien, J.H. Toney, K.K. Huff, and M.E. Lippman, Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice, Cancer Res 43:2223-2239 (1983).
6. R. Clarke, R.B. Dickson, and M.E. Lippman, Hormonal aspects of breast cancer: growth factors, drugs and stromal interactions, Crit Rev Oncol Hematol 12:1-23 (1992).
7. D.J.P. Ferguson and T.J. Anderson, Morphological evaluation of cell turnover in relation to the menstrual cycle in the nesting human breast, Br J Cancer 44:177-181 (1981).
8. M. Metzler, Biochemical toxicology of diethylstilbestrol, in: "Reviews in Biochemical Toxicology", E. Hodgson et al., Elsevier, NY, pp. 191-220 (1984).
9. T. Tsutsui, H. Maizumi, J.A. McLachlan, and J.C. Barrett, Aneuploidy induction and cell transformation by diethylstilbestrol: a possible chromosomal mechanism in carcinogenesis, Cancer Res 43:3814-3821 (1983).
10. J. Fishman, Aromatic hydroxylation of estrogens, Ann Rev Physiol 45:61-72 (1983).
11. M. Metzler, Metabolic activation of xenobiotic stilbene estrogens, Fed Proc 46:1855-1857 (1987).
12. P. Garcia-Morales, M. Saceda, N. Kenney, N. Kim, D.S. Salomon, M.M. Gottardis, H.B. Solomon, P.F. Sholler, C.V. Jordan, and M.B. Martin, Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells, J Biol Chem 269:16896-16901 (1994).
13. D. Duval, S. Durant, and F. Homo-Delarche, Non-genomic effects of steroids. Interactions of steroid molecules with membrane structures and functions, Biochim Biophys Acta 737:409-442 (1983).
14. M. Farhat, S. Abi-Younes, R. Vargas, R.M. Wolfe, R. Clarke, and P.W. Ramwell, Vascular non-genomic effects of estrogen, in: "Sex Steroids and the Cardiovascular System", P.W. Ramwell et al., Springer-Verlag, Berlin, pp. 145-159 (1992).
15. R. Clarke and M.E. Lippman, Antiestrogens resistance: mechanisms and reversal, in: "Drug Resistance in Oncology", B.A. Teicher., ed., Marcel Dekker, Inc. New York, pp. 501-536 (1992).
16. A.E. Wakeling, M. Dukes, and J. Bowler, A potent specific pure antiestrogen with clinical potential, Cancer Res 51:3867-3873 (1991).
17. H.-Y.P. Lam, Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase, Biochem Biophys Res Comm 118:27-32 (1984).
18. C.A. O'Brian, R.M. Liskamp, D.H. Solomon, and I.B. Weinstein, Triphenylethylenes: a new class of protein kinase C inhibitors, J Natl Cancer Inst 76:1243-1246 (1986).
19. B.S. Katzenellenbogen, A.M. Miller, A. Mullick, and Y.Y. Sheen, Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites, Breast Cancer Res Treat 5:231-243 (1985).
20. T. Akiyama, J. Ishida, S. Nakagawa, H. Ogawa, S. Watanabe, N. Itou, M. Shibata, and Y. Fukami, Genistein, a specific inhibitor of tyrosine-specific protein kincase, J Biol Chem 262:5592-5595 (1987).
21. A. Okura, H. Arakawa, H. Oka, T. Yoshinari, and Y. Monden, Effect of genistein on topoisomerase activity and on the growth of (val 12) Ha-ras-transformed NIH 3T3 cells, Biochem Biophys Res Commun 157:183-189 (1988).
22. H. Adlercreutz, Y. Mousavi, J. Clark, K. Hockerstedt, E. Hamalainen, K. Wahala, T. Makela, and T. Hase, Dietary phytoestrogens and cancer: in vitro and in vivo studies, J Steroid Biochem Mol Biol 41:331-337 (1992).
23. T. Hirano, K. Oka, and M. Akiba, Antiproliferative effects of synthetic and naturally occurring flavoids on tumor cells of the human breast carcinoma cell line, ZR-75-1, Res Comm Chem Path Pharm 64:69-78 (1989).
24. W.V. Welshons, C.S. Murphy, R. Koch, G. Calaf, and V.C. Jordan, Stimulation of breast cancer cells in vitro by environmental estrogens enterolactone and the phytoestrogen equol, Breast Cancer Res Treat 10:379-381 (1987).
25. P.M. Martin, K.B. Horwitz, D.S. Ryan, and W.L. McGuire, Phytoestrogen interaction with estrogen receptors in human breast cancer cells, Endocrinology 103:1860-1867 (1978).
26. W.M. Hagler, K. Tyczkowska, and P.B. Hamilton, Simultaneous occurrence of deoxynivalenol, zearalenone, and aflatoxin in 1982 scabby wheat from the Midwestern United States, Appl Environ Microbiol 47:151-154 (1984).
27. L.W. Burgess, P.E. Nelson, and T.A. Toussoun, Characterization, geographic distribution and ecology of Fusarium crookwellense sp. nov, Trans Br Mycol Soc 79:497-505 (1982).
28. Y. Luo, T. Yoshizawa, and T. Katayama, Comparative study on the natural occurrence of fusarium mycotoxins (trichothecenes and zearalenone) in corn and wheat from high- and low-risk areas for human esophageal cancer in China, Appl Environ Microbiol 56:3723-3726 (1990).
29. P. Golinski, R.F. Vesonder, D. Latus-Zietkiewicz, and J. Perkowski, Formation of fusarenone X, nivalenol, zearalenone, α-trans-zearalenol, β-trans-zearalenol, and fusarin C by Fusarium crookwellense, Appl Environ Microbiol 54:2147-2148 (1988).
30. R. Schoental, Trichothecenes, Zearalenone, and other carcinogenic metabolites of Fusarium and related microfungi, Adv Cancer Res 45:217-290 (1985).
31. T. Kuiper-Goodman, Uncertainties in the risk assessment of three mycotoxins: aflatoxin, ochratoxin, and zearalenone, Can J Physiol Pharm 68:1017-1024 (1990).
32. P.H. Hidy and R.S. Baldwin, Method of preventing pregnancy with lactone derivates, U. S. Pat June 22:3,966,274(1976).
33. W.H. Utian, Comparative trial of P-1496, a new non-steroidal oestrogen analogue, Br Med J 1:579-581 (1973).
34. Sandoz Ltd, Pharmacological trials of Frideron P-1496, Sandoz Ltd (1980).
35. A.T. Ralston, Effect of zearalanol on weaning weight of male calves, J Anim Sci 47:1203-1206 (1978).
36. J.P. Wiggins, H. Rothenbacher, L.L. Wilson, R.J. Martin, P.J. Wangness, and J.H. Ziegler, Growth and endocrine responses of lambs to zearanol implants: effects of preimplant growth rate and breed of sire, J Anim Sci 49:291-297 (1979).
37. R. Schoental, Role of podophyllotoxin in the bedding and dietary zearalenone on incidence of "spontaneous" tumors in laboratory animals, Cancer Res 34:2419(1974).
38. E.W. Thompson, D. Katz, T.B. Shima, A.E. Wakeling, M.E. Lippman, and R.B. Dickson, ICI 164,384: a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness, Cancer Res 49:6929-6934 (1989).
39. H.H. Keasling and F.W. Schueler, The relationship between estrogenic activity and chemical constitution in a group of azomethine derivatives, J Am Pharm Assoc 39:87-90 (1950).
40. J.P. Raynaud, T. Ojasco, M.M. Bouton, E. Bignon, M. Pons, and A. Crastes de Faulet, Structure-activity relationships of steroid estrogens, in: "Estrogens in the Environment", J.A. McLachlan., ed., Elsevier Science Publishing Company, New York. pp. 24-41 (1985).
41. W.L. Duax and J.F. Griffin, Structure-activity relationships of estrogenic chemicals, in: "Estrogens in the Environment", J. A. McLachlan., ed., Elsevier Science Publishing Company, New York, pp. 15-23 (1985).
42. S.A. Katzenellenbogen, B.S. Katzenellenbogen, T. Tatee, D.W. Robertson, and S.W. Landvatter, The chemistry of estrogens and antiestrogens: relationships between structure, receptor binding and biological activity, in: "Estrogens in the Environment", J.A. McLachlan., ed., Elsevier North Holland, New York, pp. 33-52 (1980).
43. W.L. Duax and C.M. Weeks, Molecular basis of estrogenicity: X-ray crystallographic studies, in: "Estrogens in the Environment", J.A. McLachlan., ed., Elsevier North Holland, New York, pp. 11-32 (1980).
44. J.P. Raynaud, T. Ojasoo, M.M. Bouton, and D. Philibert, Receptor binding as a tool in the development of new bioactive steroids, Drug Design viii: 169-214 (1979).
45. G.M. Anstead and P.R. Kym, Benz(a)anthracene diols: predicted carcinogenicity and structure-estrogen receptor binding affinity relationships, Steroids 60:383-394 (1995).
46. D. Thouvenot and R.F. Morfin, Interferences of zearalenone, zearalenol or estradiol-17β with the steroid metabolizing enzymes of the human prostate gland, J Steroid Biochem 13:1337-1345 (1980).
47. J.J. Li, S.A. Li, J.K. Klicka, and J.A. Heller, Some biological and toxicological studies of various estrogen mycotoxins and phytoestrogens, in: "Estrogens in the Environment", J.A. McLachlan., ed., Elsevier Science Publishing Company, New York, pp. 168-183 (1985).
48. B.M. Weichman and A.C. Notides, Estrogen receptor activation and the dissociation kinetics of estradiol, estriol and estrone, Endocrinology 106:434-439 (1980).
49. G. Stack, K. Korach, and J. Gorski, Relative mitogenic activities of various estrogens and antiestrogens, Steroids 54:227-243 (1989).
50. D.P. McDonnell, D.L. Clemm, T. Hermann, M.E. Goldman, and J. W. Pike, Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens, Mol Endocrinol 9:659-669 (1995).
51. R. Clarke and N. Brünner, Cross resistance and molecular mechanisms in antiestrogen resistance, Endocr Related Cancer 2:59-72 (1995).
52. R. Clarke, T. Skaar, F. Leonessa, B. Brankin, M.R. James, N. Brünner, and M.E. Lippman, The acquisition of an antiestrogen resistant phenotype in breast cancer: the role of cellular and molecular mechanisms. in: "Advances in Cancer Research", W. Hait., ed., Kluwer, Norwell, pp. in press(1996).
53. R.T. Turner, B.L. Riggs, and T.C. Spelsberg, Skeletal effects of estrogens, Endocrine Rev 15:275-300 (1994).
54. J.A. O'Keefe, E.B. Pedersen, A.J. Castro, and R.J. Handa, Estrogen receptors in hippocampal and neocortical transplants during development, Society for Neuroscience abstracts 16:(1990).
55. C.J. Coscia, W.T. Bem, G.E. Thomas, J.Y. Mamone, B.K. Levy, M. Szucs, and F.E. Johnson, Sigma and opioid receptors in human cancers, Society for Neuroscience abstracts 16:(1990).
56. R.E. Watson, Jr., M.C. Langub, Jr., and J.W. Landis, Further evidence that LHRH neurons are not directly estrogen responsive: LHRH and estrogen receptor immunoreactivity in the guinea pig brain, Society for Neuroscience abstracts 16:(1990).
57. T.L. Dellovade, J.D. Blaustein, and E.F. Rissman, Distribution of estrogen receptors in the brain of the female musk shrew: an immunocytochemical study, Society for Neuroscience abstracts 16:(1990).
58. D.W. Pfaff, Estrogens and Brain Function, Springer, New York, (1980).
59. N.G. Simon and R.E. Whalen, Hormonal regulation of aggression: evidence for a relationship among genotype, receptor binding, and behavioral sensitivity to androgens and estrogen, Aggress Behav 12:255-266 (1986).
60. L.A. Hilakivi-Clarke, P.K. Arora, M.B. Sabol, R. Clarke, R.B. Dickson, and M.E. Lippman, Alterations in behavior, steroid hormones and natural killer cell activity in male transgenic TGF-α mice, Brain Res 588:97-103 (1992).
61. G.N. Wade and J.M. Gray, Gonadal effects on food intake and adiposity: a metabolic hypothesis, Physiol Behav 22:583-593 (1979).
62. S.G. Beck, W.P. Clarke, and J. Goldfarb, Chronic estrogen effects on 5-hydroxytryptamine-mediated responses in hippocampal pyramidal cells of female rats, Neurosci Lett 106:181-187 (1989).
63. K. Sinchak, C.E. Roselli, and L.G. Clemens, Determination of aromatase activity and estrogen receptor levels in discrete brain regions from intact and castrated hybrid B6D2F1 male house mice that copulate and those that do not, Society for Neuroscience abstracts 16:(1990).
64. K.-P. Lesch and S. Gross, Estrogen receptor immunoreactivity in meningiomas, J Neurosurg 67:237-243 (1987).
65. P. Bouillot, J.F. Pellissier, B. Devictor, N. Graziani, N. Bianco, F. Grisoli, and D. Figarella-Branger, Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas, correlation with clinical and morphological data, J. Neurosurg. 81:765-773 (1994).
66. K. Iwasaki, S.A. Toms, G.H. Barnett, M.L. Estes, M.K. Gupta, and B.P. Barna, Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells, Cancer Immunol. Immunother. 40:228-234 (1995).
67. G. Baltuch, G. Shenouda, A. Langleben, and J.G. Villemure, High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression, Can. J. Neurol. Sci. 20:168-170 (1993).
68. J.P. Geisler, M.C. Wiemann, G.A. Miller, Z. Zhou, and H.E. Geisler, Estrogen and progesterone receptors in malignant mixed mesodermal tumors of the ovary, J. Surg. Oncol. 59:45-47 (1995).
69. S. Li, Relationship between cellular DNA synthesis, PCNA expression and sex steroid hormone receptor status in the developing mouse ovary, uterus and oviduct, Histochemistry 102:405-413 (1994).
70. G. Scambia, L. Catozzi, P.B. Panici, G. Ferrandina, F. Coronetta, R. Barozzi, G. Baiocchi, L. Uccelli, A. Piffanelli, and S. Mancuso, Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor, Am. J. Obstet. Gynecol. 168:71-78 (1993).
71. Y. Ohno, K. Hosokawa, T. Tamura, Y. Fujimoto, M. Kawashima, K. Koishi, and H. Okada, Endometrial oestrogen and progesterone receptors and their relationship to sonographic endometrial appearance, Hum. Reprod. 10:708-711 (1995).
72. P.C. Morris, J.R. Anderson, B. Anderson, and R.E. Buller, Steroid hormone receptor content and lymph node status in endometrial cancer, Gynecol. Oncol. 56:406-411 (1995).
73. I. Cohen, A. Shulman, M. Altaras, R. Tepper, M. Cordoba, and Y. Beyth, Estrogen and progesterone receptor expression of decidual endometrium in a postmenopausal woman treated with tamoxifen and megestrol acetate, Gynecol. Obstet. Invest. 38:127-129 (1994).
74. T. Paavonen, L.C. Andersson, and H. Adlercreutz, Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen stimulated cultures, J Exp Med 154:1935-1945 (1981).
75. A.S. Ahmed, M.J. Dauphinee, and N. Talal, Effects of short term administration of sex hormones on normal and autoimmune mice, J Immunol 134:204-210 (1985).
76. Z.M. Sthoeger, N. Chiorazzi, and R.G. Lahita, Regulation of the immune response by sex steroids. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation, J Immunol 141:91-98 (1988).
77. I. Screpanti, A. Santoni, A. Gulino, R.B. Herberman, and L. Frati, Estrogen and antiestrogen modulation of mouse natural killer activity and large granular lymphocytes, Cell Immunol 106:191-202 (1987).
78. W.E. Seaman, M.A. Blackman, T.D. Gindhart, J.R. Roubinian, J.M. Loeb, and N. Talal, β-Estradiol reduces natural killer cells in mice, J Immunol 121:2193-2198 (1978).
79. N. Hanna and M. Schneider, Enhancement of tumor metastases and suppression of natural killer cell activity by β-estradiol treatment, J Immunol 130:974-980 (1983).
80. W.E. Seaman and N. Talal, The effect of 17β-estradiol on natural killing in the mouse, in: "Natural Cell-Mediated Immunity Against Tumors", R.B. Herberman., ed., Academic Press, New York. pp. 765-777 (1980).
81. M.M. Gottardis, R.J. Wagner, E.C. Borden, and C.V. Jordan, Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro, Cancer Res 49:4765-4769 (1989).
82. L. Boix, J. Bruix, A. Castells, J. Fuster, C. Bru, J. Visa, F. Rivera, and J. Rodes, Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment?, J. Hepatol. 17:187-191 (1993).
83. S. Masood, A.B. West, and K.W. Barwick, Expression of steroid hormone receptors in benign hepatic tumors. An immunocytochemical study, Arch. Pathol. Lab. Med. 116:1355-1359 (1992).
84. D.R. Ciocca, A.D. Jorge, O. Jorge, C. Milutin, R. Hosokawa, M. Diaz Lestren, E. Muzzio, S. Schulkin, and R. Schirbu, Estrogen receptors, progesterone receptors and heat-shock 27-kd protein in liver biopsy specimens from patients with hepatitis b virus infection, Hepatology 13:838-844 (1991).
85. C.W. Hendrickse, C.E. Jones, I.A. Donovan, J.P. Neoptolemos, and P.R. Baker, Oestrogen and progesterone receptors in colorectal cancer and human colonic cancer cell lines, Br. J. Surg. 80:636-640 (1993).
86. S. Galandiuk, S. Miseljic, A.R. Yang, M. Early, M.D. McCoy, and J.L. Wittliff, Expression of hormone receptors, cathepsin d, and her-2/neu oncoprotein in normal colon and colonic disease, Arch. Surg. 128:637-642 (1993).
87. F. Meggouh, P. Lointier, and S. Saez, Sex steroid and 1,25-dihydroxyvitamin d3 receptors in human colorectal adenocarcinoma and normal mucosa, Cancer Res 51:1227-1233 (1991).
88. G. Viale, C. Doglioni, M. Gambacorta, G. Zamboni, G. Coggi, and C. Bordi, Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine rumors of the pancreas, gastrointestinal and respiratory tracts, and skin, Cancer 70:2268-2277 (1992).
89. A. Andren-Sandberg and J. Johansson, Influence of sex hormones on pancreatic cancer, Int. J. Pancreatol. 7:167-176 (1990).
90. T.O. Siu and W.B. Kwan, Hormones in chemotherapy for pancreatic cancer, chemoagents or carriers?. In Vivo. 3:255-258 (1989).
91. L.A. Hilakivi-Clarke, J. Rowland, R. Clarke, and M.E. Lippman, Psychosocial factors in the development and progression of breast cancer, Breast Cancer Res Treat 29:141-160 (1993).
92. R. Clarke, N. Brünner, D. Katz, P. Glanz, R.B. Dickson, M.E. Lippman, and F. Kern, The effects of a constitutive production of TGF-α on the growth of MCF-7 human breast cancer cells in vitro and in vivo, Mol Endocrinol 3:372-380 (1989).
93. W. Imagawa, G.K. Bandyopadhyay, and S. Nandi, Regulation of mammary epithelial cell growth in mice and rats, Endocrine Rev 11:494-523 (1990).
94. S. Coleman, G.B. Silberstein, and C.W. Daniel, Ductal morphogenesis in the mouse mammary gland: evidence supporting a role for epidermal growth factor, Dev Biology 127:304-315 (1988).
95. J. Russo and I.H. Russo, Biological and molecular bases of mammary carcinogenesis, Lab Invest 57:112-137 (1987).
96. B. Heuberger, I. Fitzka, G. Wasner, and K. Kratochwil, Induction of androgen receptor formation by epithelium-mesenchyme interaction in embryonic mouse mammary gland, Proc Natl Acad Sci USA 79:2957-2961 (1982).
97. K. Kratochwil, Organ specifity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse, Dev Biology 20:46-71 (1969).
98. K. Kratochwil, Development and loss of androgen responsiveness in the embryonic rudiment of the mouse mammary gland, Der Biology 61:358-365 (1977).
99. H. Wasner and C.W. Turner, Ontogeny of mesenchymal androgen receptors in the embryonic mouse mammary gland, Endocrinology 113:1771-1780 (1983).
100. A. Raynaud, Observations sur les modifications provoquees pas les hormones oestrogenes, du mode de developpement des mamelons des foetus de souris, C R Acad Sci 240:674-676 (1955).
101. I.H. Russo, J. Medado, and J. Russo, Endocrine influences on the mammary gland, in: "Integument and Mammary Glands", T.C. Jones et al., Springer-Verlag, Berlin, pp. 252-266 (1994).
102. M.R. Warner, Effect of various doses of estrogen to BALB/cCrgl neonatal female mice on mammary growth and branching at 5 weeks of age, Cell Tissue Kinet 9:429-438 (1976).
103. T. Tamooka and H.A. Bern, Growth of mouse mammary glands after neonatal sex hormone treatment, J Natl Cancer Inst 69:1347-1352 (1982).
104. L. Hilakivi-Clarke, E. Cho, M. Raygada, and N. Kenney, Alterations in mammary gland development following neonatal exposure to estradiol, transforming growth factor alpha, and estrogen receptor antagonist ICI 182,780, Endocrinology Submitted:(1995).
105. L.A. Jones and H.A. Bern, Cervicovaginal and mammary gland abnormalities in BALB/cCrgl mice treated neonatally with progesterone and estrogen, alone or in combination, Cancer Res 39:2560-2567 (1979).
106. R.E. Frisch, Adipose Tissue and Reproduction, Karger, Basel, (1990).
107. H. Adlercreutz, Diet and sex hormone metabolism, in: "Nutrition, Toxicity, and Cancer". I.R. Rowland., ed., CRC Press, Boca Raton, pp. 137-195 (1991).
108. D. Trichopoulos, Hypothesis: does breast cancer originate in utero?, Lancet 335:939-940 (1990).
109. A. Ekbom, D. Trichopoulos, H.O. Adami, C.C. Hsieh, and S.J. Lan, Evidence of prenatal influences on breast cancer risk, Lancet 340:1015-1018 (1992).
110. R. Anbazhagan, B. Nathan, and B.A. Gusterson, Prenatal influences and breast cancer, Lancet 340:1477-1478 (1992).
111. J. Lopez, L. Ogren, R. Verjan, and F. Talamantes, Effects of perinatal exposure to a synthetic estrogen and progestin on mammary tumorigenesis in mice, Teratology 38:129-134 (1988).
112. B.E. Walker, Tumors of female offspring of mice exposed prenatally to diethylstilbestrol, J Natl Cancer Inst 73:133-140 (1984).
113. L. Hilakivi-Clarke, R. Clarke, I. Onojafe, M. Raygada, E. Cho, and M.E. Lippman, Maternal dietary fat increases breast cancer risk among female offspring, submitted (1995).
114. T. Colton, R. Greenberg, K. Noller, L. Resseguie, C... Bennekom, T. Heeren, and Y. Zhang, Breast cancer in mothers prescribed diethylstilbestrol in pregnancy, J Am Med Assoc 269:2096-2100 (1993).
115. R.A. Rhoades and G.A. Tanner, Medical Physiology, Little, Brown and Company, Boston, (1995).
116. M.L. Casey, P.C. MacDonald, and E.R. Simpson, Textbook of Endocrinology, W.B. Saunders Company, New York, (1992).
117. B.A. Williams, K.T. Mills, C.D. Burroughs, and H.A. Bern, Reproductive alterations in female C57BL/Crgl mice exposed neonatally to zearalenone, an estrogenic mycotoxin, Cancer Lett 46:225-230 (1989).
118. C.A. Lamartiniere, J.B. Moore, J.B. Holland, and S. Barnes, Chemoprevention of mammary cancer from neonatal genistein treatment, Proc. Am. Assoc. Cancer Res. 35:Abstract 3689(1994).
119. J. Russo, G. Wilgus, and I.H. Russo, Susceptibility of the mammary gland to carcinogenesis: Differentiation of the mammary gland as determinant of tumor incidence and type of lesion, Am J Pathol 96:721-736 (1979).
120. R.W. Engelman, N.K. Day, and R.A. Good, Calorie intake during mammary development influences cancer risk: lasting inhibition of C3H/HeOu mammary tumorigenesis by prepubertal calorie restriction. Cancer Res 54:5724-5730 (1994).
121. S.Z. Haslam, Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands, Endocrinology 122:464-470 (1988).
122. Y. Folman and G.S. Pope, The interaction in the immature mouse of potent oestrogens with coumestrol, genistein and other utero-vaginotrophic compounds of low potency, J Endocrinol 34:215-225 (1966).
123. D.T. Kiang, B.J. Kennedy, S.V. Pathre, and C.J. Mirocha, Binding characteristics of zearalenone analogs to estrogen receptors, Cancer Res 38:3611-3615 (1978).
124. U.E. Mayr, Estrogen-controlled gene expression in tissue culture cells by zearalenone, FEBS Lett 239:223-226 (1988).
125. J.J. Michnovicz and H.L. Bradlow, Induction of estradiol metabolism by dietary indole-3-carbinol in humans, J Natl Cancer Inst 82:947-949 (1990).
126. H.L. Bradlow, R.E. Hershcopf, and J. Fishman, Oestradiol 16α-hydroxylase: a risk marker for breast cancer, Cancer Surv 5:573-583 (1986).
127. A. L. Harris, The epidermal growth factor receptor as a target for therapy, Cancer Cells 2:321-323 (1990).
128. Y. Matsukawa, N. Marui, T. Sakai, Y. Satomi, M. Yoshida, K. Matsumoto, H. Nishino, and A. Aoike, Genistein arrests cell cycle progression, Cancer Res 53:1328-1331 (1993).
129. F. Leonessa, W.-Y. Lim, V. Boulay, M.E. Lippman, and R. Clarke, Effect of the phytoestrogen zearalenone on human breast cancer cells, in: "Exercise, Calories, Fat and Cancer", M.M. Jacobs., ed., Plenum Press, New York, pp. 286(1992).
130. T. Fotsis, M. Pepper, H. Adlercreutz, G. Fleischmann, T. Hase, R. Montesano, and L. Schweigerer, Genistein, a dietary-derived inhibitor of in vitro angiogenesis, Proc Natl Acad Sci USA 90:2690-2694 (1993).
131. J.T.J. Kellis and L.F. Vickery, Inhibition of human estrogen synthetase (aromatase) by flavones, Science 225:1032-1034 (1984).
132. H. Adlercreutz, K. Hockerstedt, C. Bannwart, S. Bloigu, E. Hamalainen, T. Fotsis, and A. Ollus, Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metablism of estrogens and on sex hormone binding globulin (SHBG), J Steroid Biochem 27:1135-1144 (1987).
133. J.R.C. Sainsbury, A.J. Malcolm, D.R. Appleton, J.R. Farndon, and A.L. Harris, Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer, J Clin Pathol 38:1225-1228 (1985).
134. S. Nicholson, J.R.C. Sainsbury, P. Halcrow, P. Chambers, J.R. Farndon, and A.L. Harris, Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer, Lancet i: 182-184 (1989).
135. S. Nicholson, J. Richard, C. Sainsbury, P. Halcrow, P. Kelly, B. Angus, C. Wright, J. Henry, J.R. Farndon, and A.L. Harris, Epidermal growth factor receptors: results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup, Br J Cancer 63:146-150 (1991).
136. P. Bolufer, F. Miralles, A. Rodriguez, C. Vasquez, A. Lluch, J. Garcia-Conde, and T. Olmos, Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear estrogen receptors and with biological and histological tumor characteristics, Eur J Cancer 26:283-290 (1990).
137. S. Nicholson, P. Halcrow, J.R.C. Sainsbury, B. Angus, P. Chambers, J.R. Farndon, and A.L. Harris, Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer, Br J Cancer 58:810-814 (1988).
138. K.D.R. Setchell, Naturally occurring non-steroidal estrogens of dietary origin, in: "Estrogens in the environment", J.A. McLachlan., ed., Elsevier, pp. 69-85 (1985).
139. W.S. Pierpoint, Flavonoids in the human diet, in: "Plant Flavonoids in Biology and Medicine: Biochemical, Pharmacological and Structure-Activity Relationships", Alan R. Liss, Inc. New York, pp. 125-140 (1986).
140. K. Verdeal, R.R. Brown, T. Richardson, and D.S. Ryan, Affinity of phytoestrogens for estradiol-binding proteins and effect of coumesterol on growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors, J Natl Cancer Inst 64:285-290 (1980).
141. U. Mayr, A. Butsch, and S. Schneider, Validation of two in vitro test systems for estrogenic activities with zearalenone, phytoestrogens, and cereal extracts, Toxicology 74:135-149 (1992).